Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration

Sorafenib, a multiple-target tyrosine kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but provides limited benefits. Emerging evidences suggest that prolonged sorafenib treatment induces an immunosuppressive HCC microenvironment, but the underling...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lijuan, Wang, Nanya, Wang, Qiang, Fan, Xia, Xin, Yuning, Wang, Shudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008628/
https://www.ncbi.nlm.nih.gov/pubmed/36906597
http://dx.doi.org/10.1038/s41420-023-01392-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008628/
https://www.ncbi.nlm.nih.gov/pubmed/36906597
http://dx.doi.org/10.1038/s41420-023-01392-3

Ejemplares similares